Idiopathic Pulmonary Fibrosis Trends and Forecast
The future of the global idiopathic pulmonary fibrosis market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online provider markets. The global idiopathic pulmonary fibrosis market is expected to reach an estimated $6.6 billion by 2030 with a CAGR of 6.7% from 2024 to 2030. The major drivers for this market are growing occurrence of fibrotic diseases, rising adoption of advanced diagnostic tests, and expanding demand for orphan drugs.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Idiopathic Pulmonary Fibrosis by Segment
The study includes a forecast for the global idiopathic pulmonary fibrosis by drug type, distribution channel, and region.
Idiopathic Pulmonary Fibrosis Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:
• Pirfenidone
• Nintedanib
Idiopathic Pulmonary Fibrosis Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:
• Hospital Pharmacy
• Retail Pharmacy
• Online Provider
Idiopathic Pulmonary Fibrosis Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Idiopathic Pulmonary Fibrosis Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies idiopathic pulmonary fibrosis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the idiopathic pulmonary fibrosis companies profiled in this report include-
• AstraZeneca
• Bristol-Myers Squibb Company
• Boehringer Ingelheim
• GNI
• F. Hoffmann-La Roche
• Shiongi
• Mission Therapeutics
• Biogen
• Galapagos
• FibroGen
Idiopathic Pulmonary Fibrosis Market Insights
Lucintel forecasts that pirfenidone will remain the larger segment over the forecast period.
Within this market, retail pharmacy will remain the largest segment.
North America will remain the largest region over the forecast period.
Features of the Global Idiopathic Pulmonary Fibrosis Market
Market Size Estimates: Idiopathic pulmonary fibrosis market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Idiopathic pulmonary fibrosis market size by drug type, distribution channel, and region in terms of value ($B).
Regional Analysis: Idiopathic pulmonary fibrosis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different drug types, distribution channels, and regions for the idiopathic pulmonary fibrosis market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the idiopathic pulmonary fibrosis market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the idiopathic pulmonary fibrosis market size?
Answer: The global idiopathic pulmonary fibrosis market is expected to reach an estimated $6.6 billion by 2030.
Q2. What is the growth forecast for idiopathic pulmonary fibrosis market?
Answer: The global idiopathic pulmonary fibrosis market is expected to grow with a CAGR of 6.7% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the idiopathic pulmonary fibrosis market?
Answer: The major drivers for this market are growing occurrence of fibrotic diseases, rising adoption of advanced diagnostic tests, and expanding demand for orphan drugs.
Q4. What are the major segments for idiopathic pulmonary fibrosis market?
Answer: The future of the idiopathic pulmonary fibrosis market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online provider markets.
Q5. Who are the key idiopathic pulmonary fibrosis market companies?
Answer: Some of the key idiopathic pulmonary fibrosis companies are as follows:
• AstraZeneca
• Bristol-Myers Squibb Company
• Boehringer Ingelheim
• GNI
• F. Hoffmann-La Roche
• Shiongi
• Mission Therapeutics
• Biogen
• Galapagos
• FibroGen
Q6. Which idiopathic pulmonary fibrosis market segment will be the largest in future?
Answer: Lucintel forecasts that pirfenidone will remain the larger segment over the forecast period.
Q7. In idiopathic pulmonary fibrosis market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period.
Q8. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the idiopathic pulmonary fibrosis market by drug type (pirfenidone and nintedanib), distribution channel (hospital pharmacy, retail pharmacy, and online provider), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Idiopathic Pulmonary Fibrosis Market, Idiopathic Pulmonary Fibrosis Market Size, Idiopathic Pulmonary Fibrosis Market Growth, Idiopathic Pulmonary Fibrosis Market Analysis, Idiopathic Pulmonary Fibrosis Market Report, Idiopathic Pulmonary Fibrosis Market Share, Idiopathic Pulmonary Fibrosis Market Trends, Idiopathic Pulmonary Fibrosis Market Forecast, Idiopathic Pulmonary Fibrosis Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.